Imagen de Portada

Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Hsin‐Fu Lee, Yi‐Hsin Chan, Tzyy‐Jer Hsu, Chi Chuang, Pei‐Ru Li, Yung‐Hsin Yeh, Hung‐Chi Su, Fu‐Chih Hsiao, Lai‐Chu See
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
por: Cheng‐Hsien Hung, et al.
Publicado: (2025)

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study
por: Tzu‐Yang Chen, et al.
Publicado: (2024)

Metabolic Profiling Reveals Diagnostic Biomarkers for Distinguishing Myocarditis From Acute Myocardial Infarction
por: Yuting Chen, et al.
Publicado: (2025)

Improved Risk Prediction of Acute Myocardial Infarction in Patients With Stable Coronary Artery Disease Using an Amino Acid‐Assisted Model
por: Yi-Jing Zhao, et al.
Publicado: (2024)

Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study
por: Bingfu Wang, et al.
Publicado: (2026)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
por: Li‐Wen Huang, et al.
Publicado: (2025)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
por: Lee‐Yuan Lin, et al.
Publicado: (2025)

Multifunctional Hydrogel Strategies for Myocardial Infarction: From Tissue Repair to Cardiac Regeneration
por: Youze Lu, et al.
Publicado: (2024)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
por: Yi‐Ping Hung, et al.
Publicado: (2024)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
por: Yu‐Ping Chang, et al.
Publicado: (2025)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
por: Hsin‐Che Lin, et al.
Publicado: (2024)

Antagonizing CCR2 With Propagermanium Leads to Altered Distribution of Macrophage Subsets and Favorable Tissue Remodeling After Myocardial Infarction in Mice
por: Kay Weipert, et al.
Publicado: (2025)

Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects
por: Yen‐Yu Liu, et al.
Publicado: (2024)

Sodium‐Glucose Cotransporter 2 Inhibitors Use and Adverse Kidney Outcomes in Patients Receiving Contrast Media
por: Lung‐Chih Li, et al.
Publicado: (2025)

Hotspots Evolution and Cutting‐Edge Trends: A Bibliometric Analysis of Autophagy in Myocardial Infarction Studies From 2007 to 2025
por: Xiao-lin Li, et al.
Publicado: (2026)

Frontiers and Hotspot Evolution of NLRP3 Inflammasome in Myocardial Infarction Research: A Bibliometric Analysis From 2013 to 2024
por: Jin-wen Wu, et al.
Publicado: (2025)

Baseline ANA and Anti‐Ro60/SSA Antibody as Potential Predictors for Immunogenicity and Poor EULAR Response in Adalimumab‐Treated RA Patients
por: Yi-Ming Chen, et al.
Publicado: (2024)

Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus
Publicado: (2024)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes
por: Shih‐Hsuan Lin, et al.
Publicado: (2026)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
por: Ming‐Lun Yeh, et al.
Publicado: (2024)

Mechanisms of Guanxinning in Myocardial Infarction: An Integrated Approach Using Network Pharmacology, Molecular Docking, and Experimental Validation
por: Yu Jiang, et al.
Publicado: (2026)

Association Between Sodium–Glucose Cotransporter‐2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus
por: Chun-Ying Wu, et al.
Publicado: (2026)

Preventive Effect of Shenfu Injection on Arrhythmia After Percutaneous Coronary Intervention in Patients With ST‐Segment Elevation Myocardial Infarction: A Prospective Randomized Controlled Trial
por: Xiaohan Qiu, et al.
Publicado: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
por: Johnny Yau‐Cheung Chang, et al.
Publicado: (2025)

DJ‐1 as a Novel Therapeutic Target for Mitigating Myocardial Ischemia–Reperfusion Injury
por: Jia-Bin Zhou, et al.
Publicado: (2024)

Ginsenoside Rb1 Mitigates Myocardial Fibrosis Through Inhibiting Exosomal‐Derived miRNA‐21–Associated Inflammation and Cardiac Signaling
por: Shihua Wang, et al.
Publicado: (2026)

Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation
por: Kuo‐Cheng Wu, et al.
Publicado: (2024)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
por: Lucie Simonis, et al.
Publicado: (2025)

Systematic Pharmacology Combined With Experimental Validation Reveals the Apoptosis‐Related Mechanism of Simiao Yong′an (SMYA) Decoction Against Myocardial Ischemia‐Reperfusion Injury
por: Huanjie Fu, et al.
Publicado: (2026)

Verteporfin Mitigates Isoproterenol‐Induced Myocardial Hypertrophy by Attenuating IL‐6/STAT3 in Cardiac Fibroblasts
por: Sunpeng Sheng, et al.
Publicado: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
por: Huy X. Ngo, et al.
Publicado: (2024)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
por: Jee‐Fu Huang, et al.
Publicado: (2026)

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review
por: Patricia Y. Chu, et al.
Publicado: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
por: Pei‐Chien Tsai, et al.
Publicado: (2025)

Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials
por: Guotao Chu, et al.
Publicado: (2025)

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
por: Ming‐Lung Tsai, et al.
Publicado: (2024)

Aldehyde Dehydrogenase‐2 Alleviates Septic Myocardial Injury by Inhibiting Caspase‐11‐Mediated Noncanonical Pyroptosis
por: Huan Liang, et al.
Publicado: (2026)

Antiatherogenic and Cardioprotective Effects of a Xanthine Derivative KMUP‐1 in ApoE Knockout Mice
por: Erna Sulistyowati, et al.
Publicado: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
por: Tyng‐Yuan Jang, et al.
Publicado: (2025)

Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis
por: Maya Fischman, et al.
Publicado: (2025)